Serum cardiometabolic biomarkers in relation to all-cause and cause-specific mortality
Despite substantial epidemiologic evidence supports the association between cardiometabolic biomarkers and risk of cardiovascular, metabolic disease and cancer, how these biomarkers may influence all-cause and cause-specific mortality remain to be established. Previous studies were limited by the relatively small sample size, inclusion of men or women only, short duration of follow up, examination of CVD or cancer mortality only, or inadequate control for confounding. Therefore, a systematic investigation of cardiometabolic biomarkers with mortality in a large-scale cohort is needed to better understand the role of metabolic disturbances in death risk. We will utilize data from UK biobank to prospectively investigate associations of 14 serum biomarkers, including lipid profiles (i.e., Cholesterol, Direct Low Density Lipoprotein, HDL-Cholesterol, Triglyceride, Apolipoprotein A, and Lipoprotein (a)), inflammatory marker (C-reactive Protein), IGF1, HbA1c, glucose, and sex hormones (i.e., testosterone, oestradiol, sex hormone binding globulin), with the risk of all-cause and cause-specific mortality (i.e., death from CVD, cancer, and other causes).
|Lead investigator:||Dr Dong Hang|
|Lead institution:||Nanjing Medical University|